Market Overview

Teva, Takeda Announce Agreement for Glatiramer Acetate for MSTreatment in Japan

Related TEVA
Regulatory Update from Impax - Analyst Blog
Teva Unveils Generic Lunesta Tablets in US
Pfizer Loses Bid to Hold Celebrex Exclusivity to '15 (Fox Business)

Teva Pharmaceutical Industries (NYSE: TEVA) and Takeda
Pharmaceutical Company (OTC: TKPYY) today announced the signing
earlier this year of an agreement in which Teva licensed to Takeda the
right to commercialize Teva's innovative glatiramer acetate ( active
ingredient) formulation for the treatment of multiple sclerosis, in
Japan. Teva and Takeda are currently working on further agreements in
connection with the implementation of this license.

Developed by Teva, glatiramer acetate for injection is indicated for the
reduction of the frequency of relapses in relapsing-remitting multiple
sclerosis, including patients who have experienced a first clinical
episode and have MRI features consistent with multiple sclerosis. It is
considered standard treatment for relapsing-remitting multiple

See full press release

Posted-In: News Guidance Contracts Asset Sales Management Global

 

Most Popular

Related Articles (TEVA + TKPYY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free